CTOs on the Move

SHINE Technologies

www.shinefusion.com

 
Based in Janesville, Wisconsin, SHINE deploys its safe, cost-effective and environmentally friendly fusion technology in a stepwise approach. Its systems are used to inspect industrial components in aerospace, defense, energy and other sectors. SHINE`s proprietary medical isotope production processes create non-carrier-added lutetium-177 and are expected to create molybdenum-99. In the future, SHINE plans to scale its fusion technology to help solve one of energy`s toughest hurdles by recycling nuclear waste. Through a purpose-driven and phased approach, SHINE aims to generate fusion power to deliver clean, abundant energy that could transform life on Earth
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Eli Moll
 Chief Operating Officer Profile

Funding

SHINE Technologies raised $30M on 11/27/2018
SHINE Technologies raised $18M on 07/01/2019
SHINE Technologies raised $50M on 10/07/2019
SHINE Technologies raised $150M on 06/28/2021

Similar Companies

Bristol Meyers Squibb Company

Bristol Meyers Squibb Company is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Prasco Laboratories

Prasco Laboratories is a Mason, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Process Control Solutions

Process Control Solutions is a Northborough, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Adfinitas Health

Adfinitas Health (formerly MDICS) is Marylands largest private hospitalist group of physicians, nurse practitioners and physician assistants, dedicated to providing comprehensive, cost-effective, high-quality medical care to patients in hospitals, ski...

Cytovia Therapeutics

Cytovia is dedicated to the development of transformational cancer immunotherapies, addressing several of the most challenging unmet medical needs including the prevention of cancer relapse and metastasis. Cytovia focuses on Natural Killer (NK) cell biology and applies precision medicine tools to develop the right therapy for the right patient at the right stage of the disease. Cytovia has secured access to multiple advanced technologies, including allogeneic cell therapy, multispecific antibodies, and cytokines. Cytovia establishes development partnerships to accelerate time-to-market and commercialization alliances in order to optimize rapid adoption of its novel immunotherapies.